FDA Approval Process Update for Perphenazine by Zydus Pharmaceuticals
The FDA has an active application (ANDA205232) for Perphenazine submitted by Zydus Pharmaceuticals, currently under review.
Published: August 3, 2026
Updated: August 3, 2026
Author: Humanexa Intelligence
Therapeutic area: Psychiatry / Antipsychotic
Company: Zydus Pharmaceuticals
Asset: Perphenazine
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Zydus Pharmaceuticals
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's review of Zydus Pharmaceuticals' ANDA for Perphenazine is significant as it could introduce a new competitor in the antipsychotic market. This development necessitates a reassessment of market strategies to maintain competitive positioning.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's review progress and any subsequent approval announcements for ANDA205232.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.